Sandu PharmaceuticalsBOM:524703 +0.79%74 EBITDA Margin % is 5.55% as of Mar. 2026, which is 25% above its 10-year median of 4.44. GuruFocus rates BOM:524703 with a GF Score™ of 74/100 and a GF Value™ of ₹58.53 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 956 Drug Manufacturers companies, Sandu Pharmaceuticals ranks worse than 67.89% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Sandu Pharmaceuticals EBITDA Margin % Related Terms
Sandu Pharmaceuticals EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Sandu Pharmaceuticals's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524703 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sandu Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sandu Pharmaceuticals EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sandu Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Sandu Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sandu Pharmaceuticals (BOM:524703) has a EBITDA Margin % of 5.55% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sandu Pharmaceuticals and its competitors. This is 25% above median its historical median of 4.44. Over the past decade, Sandu Pharmaceuticals' EBITDA Margin % has ranged from 3.88 to 5.53. According to the industry distribution chart, Sandu Pharmaceuticals ranks #649 out of 956 companies in the Drug Manufacturers industry, placing it in the top 67.9%.
Is Sandu Pharmaceuticals' EBITDA Margin % too high?
Sandu Pharmaceuticals' current EBITDA Margin % of 5.55% is 25% above median its 10-year median of 4.44. Over the past 10 years, this metric has ranged from a low of 3.88 to a high of 5.53. The Drug Manufacturers industry median EBITDA Margin % is 12.52. Sandu Pharmaceuticals' value of 5.55% is 55.7% below this industry median. Based on the distribution chart, Sandu Pharmaceuticals ranks #649 out of 956 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Sandu Pharmaceuticals has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sandu Pharmaceuticals' EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sandu Pharmaceuticals ranks #649 out of 956 companies for EBITDA Margin %. This places Sandu Pharmaceuticals in the lower half of its industry. The industry median EBITDA Margin % is 12.52. Sandu Pharmaceuticals' value of 5.55% is 55.7% below this benchmark. Historically, Sandu Pharmaceuticals' own EBITDA Margin % has ranged from 3.88 to 5.53 over the past decade. While the company's 10-year median is 4.44 vs. the industry median of 12.52, Sandu Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.52, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sandu Pharmaceuticals's current EBITDA Margin % of 5.55% is 55.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sandu Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sandu Pharmaceuticals's current EBITDA Margin % is 5.55%, which is 25% above median its own 10-year median of 4.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sandu Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Sandu Pharmaceuticals (BOM:524703) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹58.53, compared to a current price of ₹41.92 — trading 28.4% below its estimated fair value. The current EBITDA Margin % is 5.55%, which is 25% above median its 10-year median of 4.44 and 55.7% below the Drug Manufacturers industry median of 12.52. Sandu Pharmaceuticals' overall GF Score™ is 74/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sandu Pharmaceuticals (BOM:524703), the current EBITDA Margin % is 5.55% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sandu Pharmaceuticals (BOM:524703) Overvalued in 2026?
Based on GuruFocus' analysis, Sandu Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹41.92 is trading 28.4% below its estimated GF Value™ of ₹58.53.
GuruFocus considers Sandu Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for BOM:524703:
EBITDA Margin %: 5.55% (25% above median its 10-year median of 4.44)
GF Value™: ₹58.53 vs. price of ₹41.92 (28.4% below fair value)
Industry Position: 55.7% below the Drug Manufacturers median (#649 of 956)
No single metric tells the full story. See the BOM:524703 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524703 has been successfully added to your 
